Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Effects of Basic Body Awareness Therapy on Gait and Plantar Pressure in Healthy Young Adults

14. Juli 2026 aktualisiert von: Özge ÇANKAYA, Hacettepe University

Effects of Basic Body Awareness Therapy on Spatiotemporal Gait Characteristics and Plantar Pressure Distribution in Healthy Young Adults

This interventional study will evaluate the effects of Basic Body Awareness Therapy (BBAT) on gait and plantar pressure outcomes in healthy young adults. Participants aged 18 to 25 years will receive a 12-week BBAT program delivered twice weekly by a physiotherapist trained in BBAT. Outcomes will be assessed at baseline, after the 12-week intervention, and at 3-month follow-up. The primary aim is to determine changes in gait speed and other spatiotemporal gait parameters during the 10-meter walk test. Secondary aims are to examine changes in static and dynamic plantar load distribution, right-left load sharing, and regional plantar pressure parameters. The study hypothesizes that BBAT will improve gait speed, reduce right-left differences in spatiotemporal gait parameters, improve bilateral load distribution during static stance and walking, and maintain these gains at 3-month follow-up.

Studienübersicht

Status

Rekrutierung

Detaillierte Beschreibung

Gait is a functional task requiring integrated postural control, sensorimotor processing, muscle coordination, and adaptation to the environment. Gait speed and related spatiotemporal parameters are sensitive indicators of functional status and movement capacity. Body awareness refers to the conscious perception and regulation of posture, movement quality, proprioceptive input, and interoceptive sensations. Basic Body Awareness Therapy is a physiotherapy-based mind-body approach that focuses on posture, balance, coordination, breathing, weight transfer, trunk control, and movement quality.

This study is designed as a single-group, quasi-experimental interventional study with repeated assessments. After completion of the informed consent process, demographic and health-related data will be collected. Gait and static stance measurements will be performed using Noraxon Ultium instrumented insoles. For static stance, participants will stand comfortably on both feet for one minute while plantar load distribution and right-left weight sharing are recorded. Participants will then complete the 10-meter walk test at maximum walking speed. Plantar loading data, including pressure distribution, step length, step time, stance and swing phases, and regional plantar pressure variables, will be processed using MyoResearch 3.16 software. The gait cycle will be normalized to 100%, divided into stance and swing phases, and plantar regions will be analyzed as heel, arch/midfoot, metatarsal, and toe segments.

The BBAT intervention will be delivered for 12 weeks, twice per week, with each session lasting approximately 45 to 60 minutes. Sessions will be supervised by a physiotherapist who has completed BBAT Level C training. The program will consist of low-intensity exercises focusing on awareness of contact with the floor, postural alignment, breathing and movement integration, weight transfer, trunk control, balance, and fluent movement quality. Therapy adherence will be monitored using attendance records, and adherence will be defined as participation in at least 80% of planned sessions. Measurements will be repeated after the 12-week intervention and 3 months after intervention completion to assess short-term effects and early maintenance of behavioral change.

The sample size was determined using G*Power 3.1 software. Considering the single-group design with three repeated measurements (pre-test, post-test at week 12, and 3-month follow-up), the parameters were set as a medium effect size of f = 0.25, an alpha error probability of 0.05, a power (1-β) of 0.80, a correlation among repeated measures of 0.50, and a non-sphericity correction ε = 1.00. Based on these parameters, the required sample size was calculated as 28 participants. Considering a possible dropout/follow-up loss rate of approximately 15%, the target sample size was determined as 33 participants.

Studientyp

Interventionell

Einschreibung (Geschätzt)

33

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

  • Erwachsene

Akzeptiert gesunde Freiwillige

Ja

Beschreibung

Inclusion Criteria:

  • Aged 18 to 25 years
  • Able to walk independently
  • No history of lower-extremity, spine, or balance-affecting trauma and/or surgery within the last 6 months
  • Not receiving regular Basic Body Awareness Therapy
  • Provides written informed consent

Exclusion Criteria:

  • History of neurological, vestibular, or rheumatological disease
  • Acute musculoskeletal injury
  • Serious visual or hearing impairment
  • Pain, deformity, or assistive device use that may affect walking performance
  • Participation in a physiotherapy program and/or regular exercise program within the last 6 months
  • Any condition preventing regular participation in assessment or therapy sessions

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Verhütung
  • Zuteilung: N / A
  • Interventionsmodell: Einzelgruppenzuweisung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Experimental: Basic Body Awareness Therapy-BBAT Group
Participants will receive a 12-week BBAT program, two sessions per week, with each session lasting approximately 45-60 minutes. Sessions will be supervised by a physiotherapist trained in BBAT.
The Basic Body Awareness Therapy program includes low-intensity physiotherapy exercises focused on awareness of contact with the floor, postural alignment, breathing-movement integration, weight transfer, trunk control, balance, and fluent movement quality.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change in Gait Speed
Zeitfenster: Baseline, after 12 weeks of intervention, and 3 months after intervention completion.
Gait speed will be assessed during the 10-meter walk test using Noraxon Ultium instrumented insoles. Participants will be instructed to walk at maximum walking speed on a 10-meter walkway. The best test performance will be used for analysis. The metric will be recorded in meters/second.
Baseline, after 12 weeks of intervention, and 3 months after intervention completion.
Change in Cadence
Zeitfenster: Baseline, after 12 weeks of intervention, and 3 months after intervention completion.

Cadence will be assessed during the 10-meter walk test using Noraxon Ultium instrumented insoles and processed using MyoResearch 3.16. Cadence will be recorded as the number of steps per minute.

Unit of Measure: steps/min

Baseline, after 12 weeks of intervention, and 3 months after intervention completion.
Change in Step Length
Zeitfenster: Baseline, after 12 weeks of intervention, and 3 months after intervention completion.

Step length will be assessed during the 10-meter walk test using Noraxon Ultium instrumented insoles and processed using MyoResearch 3.16. Step length will be recorded in meters.

Unit of Measure: m

Baseline, after 12 weeks of intervention, and 3 months after intervention completion.
Change in Step Time
Zeitfenster: Baseline, after 12 weeks of intervention, and 3 months after intervention completion.

Step time will be assessed during the 10-meter walk test using Noraxon Ultium instrumented insoles and processed using MyoResearch 3.16. Step time will be recorded in seconds.

Unit of Measure: s

Baseline, after 12 weeks of intervention, and 3 months after intervention completion.
Change in Stride Time
Zeitfenster: Baseline, after 12 weeks of intervention, and 3 months after intervention completion.

Stride time will be assessed during the 10-meter walk test using Noraxon Ultium instrumented insoles and processed using MyoResearch 3.16. Stride time will be recorded in seconds.

Unit of Measure: s

Baseline, after 12 weeks of intervention, and 3 months after intervention completion.
Change in Stance Phase Duration
Zeitfenster: Baseline, after 12 weeks of intervention, and 3 months after intervention completion.

Stance phase duration will be assessed during the 10-meter walk test using Noraxon Ultium instrumented insoles and processed using MyoResearch 3.16. Stance phase duration will be recorded as a percentage of the gait cycle.

Unit of Measure: %

Baseline, after 12 weeks of intervention, and 3 months after intervention completion.
Change in Swing Phase Duration
Zeitfenster: Baseline, after 12 weeks of intervention, and 3 months after intervention completion.

Swing phase duration will be assessed during the 10-meter walk test using Noraxon Ultium instrumented insoles and processed using MyoResearch 3.16. Swing phase duration will be recorded as a percentage of the gait cycle.

Unit of Measure: %

Baseline, after 12 weeks of intervention, and 3 months after intervention completion.
Change in Gait Asymmetry Index
Zeitfenster: Baseline, after 12 weeks of intervention, and 3 months after intervention completion.

The asymmetry index for gait-phase timing parameters will be calculated using the formula:

AI = [(Right - Left) / ((Right + Left)/2)] × 100

The asymmetry index will be expressed as a percentage, with higher values indicating greater gait asymmetry.

Unit of Measure: %

Baseline, after 12 weeks of intervention, and 3 months after intervention completion.

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change in Static Plantar Load Distribution
Zeitfenster: Baseline, after 12 weeks of intervention, and 3 months after intervention completion.
Static plantar load distribution will be assessed during one minute of comfortable bipedal standing using Noraxon Ultium instrumented insoles. Outcomes will include right-left load sharing and regional plantar pressure/load parameters.
Baseline, after 12 weeks of intervention, and 3 months after intervention completion.
Change in Dynamic Plantar Pressure Distribution During Walking
Zeitfenster: Baseline, after 12 weeks of intervention, and 3 months after intervention completion.
Dynamic plantar pressure variables will be recorded during the 10-meter walk test. Plantar regions will be analyzed as heel, arch/midfoot, metatarsal, and toe segments. Variables will include regional pressure distribution and bilateral differences in plantar loading
Baseline, after 12 weeks of intervention, and 3 months after intervention completion.
Therapy Adherence
Zeitfenster: Throughout the 12-week intervention period.
Attendance will be monitored using session attendance records. Therapy adherence will be defined as participation in at least 80% of planned BBAT sessions.
Throughout the 12-week intervention period.

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Hauptermittler: Özge ÇANKAYA, PhD, Saglik Bilimleri Universitesi
  • Studienleiter: Nilufer Keskin Dilbay, PhD, Saglik Bilimleri Universitesi

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

29. Juni 2026

Primärer Abschluss (Geschätzt)

29. September 2026

Studienabschluss (Geschätzt)

4. Januar 2027

Studienanmeldedaten

Zuerst eingereicht

26. Juni 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

3. Juli 2026

Zuerst gepostet (Tatsächlich)

7. Juli 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

15. Juli 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

14. Juli 2026

Zuletzt verifiziert

1. Juli 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren